PTO:S8986 (07-09)
Approved for use through 07/31/2012 CABI 908-1001
U.S. Patert and Trademack Office; U.S. DEPARTMENT OF COMMRKOE
Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it disableys a valid OMS control number

CTATEMENT UNDER 27 CER 2 72/L)

STATEMENT GROEKS OF N 3.75(b)	
Applicant/Patent Owner: MedImmune Limited	
	Filed/Issue Date: July 15, 2004
Titled Human Antibody Molecules For IL-13	
Medimmune Limited	, a corporation
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is	
the assignee of the entire right, title, and it.	interest in;
an assignee of less than the entire right, t     (The extent (by percentage) of its owners	uitle, and interest in hip interest is%); or
3 the assignee of an undivided interest in the	ne entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtu	ue of either:
An assignment from the inventor(s) of the the United States Patent and Trademark copy therefore is attached.	patent application/patent identified above. The assignment was recorded in Office at Reel 018848, Frame 0655, or for which a
OR	
Land 177	patent application/patent identified above, to the current assignee as follows:
1. From:	То:
	the United States Patent and Trademark Office at
Reel	Frame, or for which a copy thereof is attached.
2. From:	To:
The document was recorded in	the United States Patent and Trademark Office at
Reel,	Frame, or for which a copy thereof is attached.
3. From:	То:
The document was recorded in	the United States Patent and Trademark Office at
Reel	Frame or for which a copy thereof is attached.
Additional documents in the chain of title	are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the docu- or concurrently is being, submitted for recordar	imentary evidence of the chain of title from the original owner to the assignee was, tion pursuant to 37 CFR 3.11.
(NOTE: A separate copy (i.e., a true copy of tagget accordance with 37 CFR Part 3, to record the	the original assignment document(s)) must be submitted to Assignment Division in assignment in the records of the USPTO. <u>See</u> MPEP 302.08]
The undersigned (whose fitte is supplied below) is au Skinature	thorized to act on behalf of the assignee.  Agrist 24, 2011  Date
Patrick Scott Alban	Associate GC, Head of IP
Printed or Typed Name	Title


This collection of information is required by 37 CFR 373(b). The information is required to obtain or retain a benefit by the public which is to fill (and by the USPTO to process) an application. Confidentially is governed by 36 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take it 2 finitives to complete, including agreement, and submitting the completed spickculon from the USPTO. Time will vary deposing upon the individual case. Any common to the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Officer, U.S. Patiert and Trademark Officer. Despitation of Commerce P.O. Boat 1450, Alexandria, V.B. 2321-1450. D. DIOT SEND FEES FEE OR COMPLIFIED FORMS TO THIS DIOTESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) (equires that you be given certain information in connection with your submission of the stakehed form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 39 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

## The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whem the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended. Dursant to 5 LI SC. 5524(m)
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator. General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2804 and 2806. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.





## UNITED STATES PATENT AND TRADEMARK OFFICE

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

FEBRUARY 02, 2007

HELLER EHRMAN LLP 275 MIDDLEFIELD ROAD MENLO PARK, CA 94025

PTAS

\*500217785A\*

\*500217785A\*

2/005

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 02/02/2007

REEL/FRAME: 018848/0655 NUMBER OF PAGES: 7

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS). DOCKET NUMBER: 43518-0001

ASSIGNOR:

MONK, PHILLIP DAVID

WILHEIM

DOC DATE: 12/09/2005

ASSTONOR.

JERMUTUS, LUTZ ULRICH JOCHEN

DOC DATE: 12/13/2005

ASSTGNOR:

MINTER, RALPH RAYMOND

DOC DATE: 12/13/2005

ASSIGNOR:

SHORROCK, CELIA PATRICIA

DOC DATE: 11/25/2005

ASSTGNEE:

CAMBRIDGE ANTIBODY TECHNOLOGY

P.O. Box 1450, Alexandria, Virginia 22313-1450 - www.uspro.sov

USPTO 2/7/2007 10:39:42 PM PAGE 3/005 Fax Server

TO:HELLER EHRMAN LLP COMPAN 275 MIDDLEFIELD ROAD

LIMITED MILSTEIN BUILDING, GRANTA PARK CAMBRIDGE, UNITED KINGDOM CB1 6GH

018848/0655 PAGE 2

SERIAL NUMBER: 10564647 PATENT NUMBER:

FILING DATE; ISSUE DATE:

TITLE: HUMAN ANTIBODY MOLECULES FOR IL-13

ASSIGNMENT SERVICES BRANCH PUBLIC RECORDS DIVISION

We hereby certify that this is a true and complete copy of the original document.

Mills + New CCP

Dated: 06.11.07

Mills & Resve LLP Solicitors 1 St James Court Whitefrians Netwich



## CERTIFICATE OF INCORPORATION ON CHANGE OF NAME

Company No. 2451177

The Registrar of Companies for England and Wales hereby certifies that

CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED

having by special resolution changed its name, is now incorporated under the name of

MEDIMMUNE LIMITED

Given at Companies House, Cardiff, the 29th October 2007



